Biogen Inc. develops and commercializes biopharmaceutical therapies focused on neurodegenerative diseases, rare diseases and adjacent specialty areas. Company news commonly covers Alzheimer’s disease therapy LEQEMBI with Eisai, spinal muscular atrophy treatment SPINRAZA, Friedreich’s ataxia therapy SKYCLARYS, postpartum depression therapy ZURZUVAE, ALS therapy QALSODY, multiple sclerosis products and CD20 collaboration revenue tied to Roche-partnered medicines.
Recurring updates include FDA review activity, supplemental biologics license applications, global regulatory status, clinical development programs, collaboration and licensing economics, asset-rights transactions and product demand trends. Biogen news also includes financial results, acquired in-process research and development expense, governance changes and corporate-status disclosures typical of a Nasdaq-listed biotechnology issuer.
Biogen announced new data on SPINRAZA, demonstrating its long-term efficacy and safety in treating spinal muscular atrophy (SMA). Presenting at the 72nd AAN annual meeting, findings from the SHINE study show motor function improvements or stabilization in patients treated for up to six and a half years. Key highlights include significant benefits observed in infants and young adults, with a consistent safety profile. Over 10,000 individuals have been treated with SPINRAZA, enhancing its position as the primary SMA treatment.
Summary not available.